Roche’s Actemra Gets FDA Panel Vote Of Confidence With Robust P-vigilance
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis Drugs Advisory Committee selects more cautious starting dose for Roche’s rheumatoid arthritis therapy during July 29 meeting.